Nexera X2 –X-ceptional insights - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Nexera X2 – X-ceptional insights

Ultra-high sensitivity, expanded flexibility, increased stability and robustness - the new Nexera X2 UHPLC system targets routine analysis and applications in highly regulated environments demanding complex system setups.

System flexibility
The system flexibility is based on software features which control multiple gradients in a single system. This enables automated solvent blending on each pump in a binary gradient setup. The software has been adapted to meet the requirements for use in highly regulated environments.

Stability
Stability in gradient use has been improved by pump side modifications. Furthermore, design changes on inlet valve and degassing unit minimize air bubbles passing through the flow line and reduce their negative effects on stability and performance. For addressing specific applications, additional micro reactor based mixing devices can be selected accordingly. A newly designed low volume quaternary option reduces the system volume to meet UHPLC needs while enabling a better inter-system method transfer.

Sensitivity
The new SPD-M30A photodiode array detector is perfectly suited ultra-high sensitive applications using a capillary cell with low dispersion. Total reflection and a high energy deuterium lamp guarantee a low noise level. A novel temperature control principle decreases baseline drift and offers improved reliability even under changing environment conditions. Together with ultra-high speed data acquisition, software features which maximize resolution on the PDA while enabling peak deconvolution squeeze the maximum information out of a single analysis.

For more information please visit www.shimadzu.eu.

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
13%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search

Click here